Mortazavi, N., Esmaeilzadeh, H., Abbasinazari, M., Babaie, D., Alyasin, S., Nabavizadeh, H., Esmailzadeh, E. (2017). Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease. Iranian Journal of Pharmaceutical Research, 16(4), 1639-1647. doi: 10.22037/ijpr.2017.2141
Negar Mortazavi; Hossein Esmaeilzadeh; Mohammad Abbasinazari; Delara Babaie; Soheila Alyasin; Hesamodin Nabavizadeh; Elmira Esmailzadeh. "Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease". Iranian Journal of Pharmaceutical Research, 16, 4, 2017, 1639-1647. doi: 10.22037/ijpr.2017.2141
Mortazavi, N., Esmaeilzadeh, H., Abbasinazari, M., Babaie, D., Alyasin, S., Nabavizadeh, H., Esmailzadeh, E. (2017). 'Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease', Iranian Journal of Pharmaceutical Research, 16(4), pp. 1639-1647. doi: 10.22037/ijpr.2017.2141
Mortazavi, N., Esmaeilzadeh, H., Abbasinazari, M., Babaie, D., Alyasin, S., Nabavizadeh, H., Esmailzadeh, E. Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease. Iranian Journal of Pharmaceutical Research, 2017; 16(4): 1639-1647. doi: 10.22037/ijpr.2017.2141
Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease
1Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Allergy research center, Shiraz University of Medical Sciences, Shiraz
3Department of Allergy and Clinical Immunology, Mofid Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Allergy research center, Shiraz University of Medical Sciences, Shiraz, Iran
5Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
This study aimed to investigate the efficacy and the underlining mechanism of aspirin desensitization among patients with Aspirin Exacerbated Respiratory Disease (AERD). Thirtyeight patients, who had undergone an aspirin challenge test and were diagnosed as having AERD, were engaged in a double-blind randomized clinical trial. They were divided into two groups—an active group of patients who went through aspirin desensitization, and the control group, receiving placebo. Clinical symptoms and the quality of life of the patients—in addition to the levels of interleukin 4 and 5 (IL4), (IL5)—were documented at the beginning of the study and again after six months of aspirin desensitization. The quality of life of the patients was significantly higher in the active group after six months (P = 0.001). Medication requirements and symptom score were manifested to be significantly lower in the active group after six months than at the beginning of the study (P = 0.005, 0.017 respectively). Forced expiratory volume in the second one (FEV1) was, also, significantly higher in the active group after six months of the study (P = 0.032). IL5 was found to be significantly lower in the active group after six months (P = 0.019). However, no significant difference was observed in the levels of IL4 between the two groups (P = 0.152). The study revealed that aspirin desensitization can improve the quality of life of patients with AERD, lessen their symptoms and medication requirements, lower their levels of IL5, and improve some pulmonary function tests such as FEV1.
Top